NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) posted its earnings results on Monday, November, 4th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.17. The company had revenue of $13.15 million for the quarter, compared to analyst estimates of $1.61 million. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 brokers have issued 12-month price targets for Karyopharm Therapeutics' stock. Their forecasts range from $5.00 to $37.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $22.33 in the next year. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

Media headlines about KPTI stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Karyopharm Therapeutics.

Karyopharm Therapeutics saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 9,570,000 shares, a decline of 6.8% from the December 15th total of 10,270,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the short-interest ratio is presently 7.6 days. Approximately 17.2% of the company's stock are sold short. View Karyopharm Therapeutics' Current Options Chain.

Some companies that are related to Karyopharm Therapeutics include BridgeBio Pharma (BBIO), Evotec (EVTCY), Allakos (ALLK), United Therapeutics (UTHR), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Micron Technology (MU), Alibaba Group (BABA), Caladrius Biosciences (CLBS), Celgene (CELG), GW Pharmaceuticals PLC- (GWPH) and Sorrento Therapeutics (SRNE).

Karyopharm Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Private Capital Advisors Inc. (0.17%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $17.86.

Karyopharm Therapeutics has a market capitalization of $1.12 billion and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]